Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQTNASDAQ:BNTCNASDAQ:DYNNASDAQ:EWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$13.72-0.3%$14.00$7.86▼$17.75$1.63B1.772.20 million shs778,148 shsBNTCBenitec Biopharma$13.14+3.1%$14.29$7.05▼$17.15$344.93M0.3755,613 shs74,946 shsDYNDyne Therapeutics$9.05+1.2%$11.77$6.36▼$47.45$1.03B1.081.81 million shs1.99 million shsEWTXEdgewise Therapeutics$12.96-0.4%$14.71$10.60▼$38.12$1.36B0.251.19 million shs361,183 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics+0.07%-4.91%+2.08%-14.85%+47.96%BNTCBenitec Biopharma+5.20%-3.19%-18.39%-2.08%+46.44%DYNDyne Therapeutics+3.00%-14.20%-29.61%-5.10%-74.20%EWTXEdgewise Therapeutics+1.48%-9.21%-11.44%-4.20%-29.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.0403 of 5 stars3.41.00.00.02.21.70.6BNTCBenitec Biopharma1.7157 of 5 stars3.62.00.00.01.50.80.0DYNDyne Therapeutics3.5139 of 5 stars4.53.00.00.02.42.50.0EWTXEdgewise Therapeutics2.6831 of 5 stars3.43.00.00.01.93.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8037.08% UpsideBNTCBenitec Biopharma 3.22Buy$23.8381.38% UpsideDYNDyne Therapeutics 3.00Buy$41.13354.42% UpsideEWTXEdgewise Therapeutics 2.80Moderate Buy$40.00208.76% UpsideCurrent Analyst Ratings BreakdownLatest BNTC, ARQT, DYN, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025EWTXEdgewise TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$42.006/26/2025DYNDyne TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/25/2025DYNDyne TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/24/2025DYNDyne TherapeuticsSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$13.006/18/2025DYNDyne TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/18/2025DYNDyne TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $32.006/17/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/11/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$37.006/5/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$48.006/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.005/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$212.82M7.68N/AN/A$1.35 per share10.16BNTCBenitec Biopharma$80K4,311.56N/AN/A$4.68 per share2.81DYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/13/2025 (Estimated)BNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%N/ADYNDyne Therapeutics-$317.42M-$3.59N/AN/AN/AN/A-52.83%-48.84%8/11/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.95%-29.45%8/6/2025 (Estimated)Latest BNTC, ARQT, DYN, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/8/2025Q1 2025EWTXEdgewise Therapeutics-$0.45-$0.43+$0.02-$0.43N/AN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.753.553.37BNTCBenitec Biopharma0.0114.8014.80DYNDyne TherapeuticsN/A20.3520.35EWTXEdgewise TherapeuticsN/A20.9920.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ABNTCBenitec Biopharma52.19%DYNDyne Therapeutics96.68%EWTXEdgewise TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%BNTCBenitec Biopharma1.30%DYNDyne Therapeutics14.14%EWTXEdgewise Therapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million108.00 millionOptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataDYNDyne Therapeutics100113.67 million97.59 millionOptionableEWTXEdgewise Therapeutics60105.20 million80.79 millionOptionableBNTC, ARQT, DYN, and EWTX HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJuly 3 at 10:00 AM | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Edgewise Therapeutics (EWTX) and Arcturus Therapeutics (ARCT)July 2 at 10:52 PM | theglobeandmail.com13 Best Up and Coming Stocks to Invest In NowJuly 2 at 12:49 PM | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJuly 2 at 10:00 AM | prnewswire.comWhat is HC Wainwright's Forecast for EWTX Q2 Earnings?July 2 at 7:41 AM | marketbeat.comEdgewise Therapeutics stock initiated with Buy rating at H.C. WainwrightJuly 1 at 10:47 PM | investing.comHC Wainwright Initiates Coverage on Edgewise Therapeutics (NASDAQ:EWTX)July 1 at 2:59 AM | americanbankingnews.comHC Wainwright & Co. Initiates Coverage of Edgewise Therapeutics (EWTX) with Buy RecommendationJune 30 at 5:59 PM | msn.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up - Should You Buy?June 30 at 12:15 PM | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Earns Buy Rating from Analysts at HC WainwrightJune 30 at 8:20 AM | marketbeat.comEdgewise Therapeutics stock holds at $16 target amid trial concernsJune 27, 2025 | investing.comEdgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies - Yahoo FinanceJune 27, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJune 27, 2025 | prnewswire.comEdgewise Therapeutics stock falls after FDA deems data insufficient for accelerated approvalJune 26, 2025 | za.investing.comEdgewise falls after data for muscular dystrophy therapyJune 26, 2025 | msn.comEdgewise Therapeutics Shares Drop After FDA Withholds Accelerated Approval for Muscle Disorder DrugJune 26, 2025 | msn.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Here's WhyJune 26, 2025 | marketbeat.comEdgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular DystrophiesJune 26, 2025 | prnewswire.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Stake Boosted by GAMMA Investing LLCJune 18, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 3.8% - What's Next?June 16, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and Edgewise Therapeutics (EWTX)June 13, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseTop Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure BoomJoby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsBy Jeffrey Neal Johnson | June 4, 2025View Joby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsBNTC, ARQT, DYN, and EWTX Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$13.72 -0.05 (-0.33%) Closing price 03:58 PM EasternExtended Trading$13.72 0.00 (0.00%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Benitec Biopharma NASDAQ:BNTC$13.14 +0.40 (+3.14%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Dyne Therapeutics NASDAQ:DYN$9.05 +0.11 (+1.23%) Closing price 03:57 PM EasternExtended Trading$8.99 -0.06 (-0.62%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Edgewise Therapeutics NASDAQ:EWTX$12.96 -0.06 (-0.42%) Closing price 01:04 PM EasternExtended Trading$12.96 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
